The research groups

Some of the groups have expertise in analysing intracellular trafficking and signalling, and how these processes control cell growth and cancer development. Other groups collaborate directly with clinicians to identify distinctive parameters of cancer cells, including nuclear aberrations, chromosomal rearrangements, DNA mutation and hypermethylation, dysregulated gene transcription, and aberrant mRNA splicing. A third category of personnel specialises in advanced statistical treatment of data, at the single-cell, single-patient, and multi-patient levels. The basic idea of CCB is that structured co-operations across the disciplines will yield faster and better progress in cancer research than what can be obtained by the constituent groups alone. In particular, the joint efforts are expected to lead to identification of novel biomarkers for early detection and subclassification of lymphomas, colorectal cancer and prostate cancer. This will have direct implications for future cancer therapy.